AVALON GLOBOC.NEW -,0001
AVALON GLOBOC.NEW -,0001
Action · US05344R2031 · ALBT · A3D4QG (XNCM)
Aperçu Indicateurs financiers
2,99 EUR
-4,48 % -0,14 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 17:46

Cours actuels de AVALON GLOBOC.NEW -,0001

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
ALBT
USD
06.06.2025 17:46
3,41 USD
3,42 USD
-0,15 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
-0,45 % -0,15 % -9,75 % -52,47 % -22,41 % -54,13 % -98,73 %

Profil de l'entreprise pour AVALON GLOBOC.NEW -,0001 Action

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Données de l'entreprise

Nom AVALON GLOBOC.NEW -,0001
Société Avalon GloboCare Corp.
Symbole ALBT
Site web https://www.avalon-globocare.com
Marché d'origine XNCM Frankfurt
WKN A3D4QG
ISIN US05344R2031
Type de titre Action
Secteur Real Estate
Industrie Real Estate - Services
PDG Dr. David K. Jin M.D., Ph.D.
Pays États-Unis d'Amérique
Devise EUR
Employés 0,0 T
Adresse 4400 Route 9 South, 07728 Freehold
Date d'introduction en bourse 2018-03-27

Fractionnements d'actions

Date Fractionnement
28.10.2024 1:15

Changements d'identifiant

Date De À
10.11.2022 AVCO ALBT

Symboles boursiers

Nom Symbole
NASDAQ ALBT

Autres actions

Les investisseurs qui détiennent AVALON GLOBOC.NEW -,0001 ont également les actions suivantes dans leur portefeuille :
KARELIA TOBAC. NA EO11,83
KARELIA TOBAC. NA EO11,83 Action
UBS (LUX) MONEY MARKET FUND - USD I-X-ACC
UBS (LUX) MONEY MARKET FUND - USD I-X-ACC ETF
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025